Cardiff Oncology Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Cardiff Oncology's earnings have been declining at an average annual rate of -20.9%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 16.7% per year.
Belangrijke informatie
-20.9%
Groei van de winst
32.6%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | 16.7% |
| Rendement op eigen vermogen | -78.0% |
| Nettomarge | -6,147.5% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Oct 09
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
Oct 04We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely
Jun 19Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Cardiff: The Pfizer Interest Is Interesting
Dec 15Circling Back On Cardiff Oncology
Oct 12Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 26Cardiff Oncology: Current Slump Doesn't Look Right
Jun 14Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Apr 29How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?
Feb 28What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?
Jan 24Opbrengsten en kosten
Hoe Cardiff Oncology geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -41 | 12 | 0 |
| 31 Mar 24 | 1 | -40 | 13 | 0 |
| 31 Dec 23 | 0 | -41 | 13 | 0 |
| 30 Sep 23 | 0 | -41 | 13 | 0 |
| 30 Jun 23 | 0 | -40 | 14 | 0 |
| 31 Mar 23 | 0 | -39 | 12 | 0 |
| 31 Dec 22 | 0 | -39 | 13 | 0 |
| 30 Sep 22 | 0 | -39 | 14 | 0 |
| 30 Jun 22 | 0 | -38 | 14 | 0 |
| 31 Mar 22 | 0 | -34 | 14 | 0 |
| 31 Dec 21 | 0 | -28 | 12 | 0 |
| 30 Sep 21 | 0 | -25 | 11 | 0 |
| 30 Jun 21 | 0 | -23 | 10 | 0 |
| 31 Mar 21 | 0 | -24 | 9 | 0 |
| 31 Dec 20 | 0 | -23 | 8 | 0 |
| 30 Sep 20 | 0 | -20 | 6 | 0 |
| 30 Jun 20 | 0 | -20 | 6 | 0 |
| 31 Mar 20 | 0 | -17 | 6 | 0 |
| 31 Dec 19 | 0 | -17 | 6 | 0 |
| 30 Sep 19 | 0 | -17 | 6 | 0 |
| 30 Jun 19 | 0 | -16 | 6 | 0 |
| 31 Mar 19 | 0 | -19 | 7 | 0 |
| 31 Dec 18 | 0 | -19 | 8 | 0 |
| 30 Sep 18 | 0 | -18 | 8 | 0 |
| 30 Jun 18 | 1 | -18 | 11 | 0 |
| 31 Mar 18 | 1 | -20 | 11 | 0 |
| 31 Dec 17 | 1 | -25 | 12 | 0 |
| 30 Sep 17 | 0 | -31 | 14 | 0 |
| 30 Jun 17 | 0 | -37 | 16 | 0 |
| 31 Mar 17 | 0 | -39 | 19 | 0 |
| 31 Dec 16 | 0 | -39 | 22 | 0 |
| 30 Sep 16 | 0 | -38 | 22 | 0 |
| 30 Jun 16 | 0 | -31 | 21 | 0 |
| 31 Mar 16 | 0 | -31 | 19 | 0 |
| 31 Dec 15 | 0 | -27 | 14 | 0 |
| 30 Sep 15 | 0 | -25 | 14 | 0 |
| 30 Jun 15 | 0 | -27 | 12 | 0 |
| 31 Mar 15 | 0 | -18 | 10 | 0 |
| 31 Dec 14 | 0 | -14 | 9 | 0 |
| 30 Sep 14 | 0 | -11 | 7 | 0 |
| 30 Jun 14 | 0 | -10 | 8 | 0 |
| 31 Mar 14 | 0 | -14 | 7 | 0 |
| 31 Dec 13 | 0 | -12 | 7 | 0 |
Kwaliteitswinsten: CRDF is currently unprofitable.
Groeiende winstmarge: CRDF is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: CRDF is unprofitable, and losses have increased over the past 5 years at a rate of 20.9% per year.
Versnelling van de groei: Unable to compare CRDF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: CRDF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: CRDF has a negative Return on Equity (-77.99%), as it is currently unprofitable.